WARREN , R.; ARMSTRONG , A.; GOODERHAM, M.; STROBER , B.; THACI, D.; IMAFUKU, S.; SOFEN, H.; SPELMAN, L.; KORMAN, N.; ZHENG, M.; COLSTON, E.; THROUP , J.; KUNDU, S.; KISA, R.; BANERJEE, S.; BLAUVELT, A. . Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 2, p. s4, 2022. DOI: 10.25251/skin.6.supp.4. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/1520. Acesso em: 1 jul. 2024.